CSTL
Castle Biosciences, Inc.
CSTL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CSTL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
CSTL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CSTL PE Valuation
CSTL has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CSTL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
CSTL has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CSTL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.75 | -$0.30 |
| Q2 2026 | -$0.64 | -$0.29 |
| Q1 2026 | -$0.42 | -$0.23 |
| Q4 2025 | -$0.83 | -234% |
| Q3 2025 | -$0.45 | -305% |
| Q2 2025 | -$0.35 | -$0.23 |
| Q1 2025 | -$0.19 | +$0.94 |
| Q4 2024 | $0.62 | +$2.76 |
CSTL is still losing money, but far less than before: $0.75 per share over the past year, against $3.35 at its worst in mid-2023.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over CSTL on earnings, with more consistent year-over-year improvement.
CSTL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.9M | +24% |
| Q2 2026 | $103.5M | +20% |
| Q1 2026 | $83.7M | -4.9% |
| Q4 2025 | $87M | +0.8% |
| Q3 2025 | $83M | -3.2% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88M | +21% |
| Q4 2024 | $86.3M | +31% |
CSTL's revenue is growing: $103M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.6% | +5.5 points |
| Q2 2026 | -3% | +2 points |
| Q1 2026 | -22% | +9.7 points |
| Q4 2025 | -4.4% | -9.1 points |
| Q3 2025 | -8.2% | -14 points |
| Q2 2025 | -4.9% | -11 points |
| Q1 2025 | -32% | -24 points |
| Q4 2024 | 4.7% | +13 points |
CSTL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CSTL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CSTL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.2M | +57% |
| Q2 2026 | $6.6M | -43% |
| Q1 2026 | -$34.6M | -$23.8M |
| Q4 2025 | $19.7M | +18% |
| Q3 2025 | $7.8M | -54% |
| Q2 2025 | $11.6M | -38% |
| Q1 2025 | -$10.8M | +$5.2M |
| Q4 2024 | $16.8M | +14% |
CSTL still generates free cash flow, though less than at its 2025 peak: $4M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CSTL on cash flow, with more consistent year-over-year improvement.
CSTL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +234K shares |
| 1 year | +5.4% | +1.6M shares |
| 3 years | +14% | +3.8M shares |
| 5 years | +21% | +5.3M shares |
| Available history | +64% | +11.9M shares |
CSTL has 31M diluted shares, up 5.4% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CSTL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CSTL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | -3.7x | Net Cash |
| Q1 2025 | -2.8x | Net Cash |
| Q4 2024 | -4.5x | Net Cash |
| Q3 2024 | -6.8x | Net Cash |
| Q2 2020 | -19.8x | Net Cash |
| Q1 2020 | -8.1x | Net Cash |
| Q4 2019 | -9.6x | Net Cash |
CSTL has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CSTL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 63.5 | Neutral |
CSTL's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CSTL PE vs Healthcare Sector
| Metric | CSTL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CSTL has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CSTL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.4 | 0.3% above |
| 20 week MA | $31.5 | 9.6% above |
| 50 week MA | $30.0 | 15% above |
| 100 week MA | $26.4 | 31% above |
| 200 week MA | $24.4 | 41% above |
CSTL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CSTL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.0 | $71.3 | +110% |
| 2021 | $71.3 | $42.6 | -40% |
| 2022 | $42.6 | $23.2 | -45% |
| 2023 | $23.2 | $21.6 | -7.1% |
| 2024 | $21.6 | $26.8 | +24% |
| 2025 | $26.8 | $39.4 | +47% |
| 2026 YTD | $39.4 | $34.5 | -12% |
CSTL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.